Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics

Leukemia

Volumn 25, Issue 8, 2011, Pages 1361-1364

  Bacher, U ^a   Kern, W ^b   Alpermann, T ^b   Schnittger, S ^b   Kohlmann, A ^b   Klein, H U ^c   Dugas, M ^c   Haferlach, C ^b   Haferlach, T ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEBPA PROTEIN; FLT3 LIGAND; HEMOGLOBIN; IDH1 PROTEIN; PEPTIDES AND PROTEINS; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLAST CELL; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CD34 SELECTION; CELL COUNT; CELL STRUCTURE; CHROMOSOME BANDING PATTERN; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; MYELOBLAST; MYELODYSPLASTIC SYNDROME; ONCOGENE N RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; RISK ASSESSMENT; UNIVARIATE ANALYSIS;

EID: 80051791993     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.80     Document Type: Letter

References (8)

1. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997;90:2969-2977. (Pubitemid 27444190)
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
3. Albitar M, Beran M, O'Brien S, Kantarjian H, Frieriech E, Keating M et al. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood 2000;96:372-373. (Pubitemid 30456499)
4. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-365.
5. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors of response and overall survival in 282 higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
6. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005;11:3604-3608. (Pubitemid 40685574)
7. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di MM et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010;34:1576-1588.
8. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-569.